A proposed securities suit against The Ensign Group, Inc. links three June share declines to reports alleging care and licensing problems, while Ensign expanded its buyback authorization between two of the cited drops.
Nicholas Perusek filed the complaint Oct. 8 in the U.S. District Court for the Central District of California. It names Ensign, CEO Barry R. Port and CFO Suzanne D. Snapper as defendants, and proposes a class covering investors who acquired Ensign securities from Feb. 10, 2022, through June 18, 2026. The filing alleges the defendants misled investors or withheld information about company operations. Those claims are allegations, not court findings; Rosen Law Firm says no class has been certified.
The complaint puts Ensign’s June 8 closing price at $156.42, 8.15% below its June 5 close of $170.30. That move followed a Hunterbrook Media report alleging staffing at Ensign facilities fell short of residents’ care needs. Hunterbrook estimated a five million-hour nursing-care gap from July through November 2024 and said closing it would cost about $161 million. Its report disclosed that an affiliated investment operation held a short position in Ensign.
For June 11, the complaint records a close of $147.13, 2.98% below the prior session, after Muddy Waters Research alleged some facilities used administrator licenses held by people who were not generally present or managing them. Muddy Waters said its team found licensing-related warning signs at 12 of 57 facilities visited and disclosed it held a short position in Ensign at publication, a position that could change. The complaint also associates a June 18 close of $153.65, down 1.4% from the prior session, with a Hunterbrook follow-up report.
On June 15, between the latter two cited declines, Ensign announced a $60 million increase to its share-repurchase authorization, bringing the total to $100 million. The company said the authorization did not commit it to buy a particular number of shares. Its release did not directly address the research reports.
Rosen Law Firm says investors seeking appointment as lead plaintiff must file by Dec. 7. The firm says investors may qualify for a potential recovery without taking that role.
